NCT00495144View on ClinicalTrials.gov

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

June 30, 2012

Conditions
TumorsHypoxia
Interventions
DRUG

TH-302

Trial Locations (7)

37203

Sarah Cannon Research Institute, Nashville

46202

Indiana University Simon Cancer Center, Indianapolis

55905

Mayo Clinic Rochester, Rochester

75201

Mary Crowley Cancer Research Centers, Dallas

85258

TGen Drug Development Services, Scottsdale

85259

Mayo Clinic Arizona, Scottsdale

94117

St. Mary's Medical Center, San Francisco

Sponsors
All Listed Sponsors
lead

Threshold Pharmaceuticals

INDUSTRY

NCT00495144 - A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter